Novelix Pharmaceuticals Partners With German Institute To Scale Astaxanthin Production Globally

Image Source: Derm-Biome Pharmaceuticals

Novelix Pharmaceuticals Ltd has entered into a strategic collaboration with GMBU e.V., Halle (Saale), Germany, to commercialize Astaxanthin production using proprietary biotechnology. The partnership includes technology transfer and aims to establish a GMP-certified facility in Hyderabad to serve global markets including Europe, North America, and India.

Collaboration targets global nutraceutical demand

Novelix Pharmaceuticals Ltd has announced a landmark partnership with German research institute GMBU e.V. to bring Astaxanthin—a powerful antioxidant—to market at commercial scale. The collaboration involves a technology transfer agreement that will enable Novelix to cultivate Haematococcus pluvialis, the microalgae source of Astaxanthin, using GMBU’s proprietary methods.

The production will be based at Novelix’s Hyderabad facility, which is being upgraded to meet GMP certification standards for global supply.

Astaxanthin’s health benefits and market potential

Astaxanthin is widely recognized for its potent antioxidant properties and is used in dietary supplements, skincare, and pharmaceutical formulations. The global demand for natural antioxidants is rising, driven by consumer interest in preventive health and wellness.

Novelix aims to position itself as a leading supplier of high-purity Astaxanthin for both B2B and retail segments, leveraging GMBU’s cultivation expertise and its own manufacturing infrastructure.

Key highlights of the partnership

- Novelix Pharmaceuticals collaborates with GMBU e.V., Germany
- Technology transfer enables Astaxanthin production from Haematococcus pluvialis
- GMP-certified facility to be established in Hyderabad
- Target markets include Europe, North America, and India
- Astaxanthin known for antioxidant and anti-inflammatory benefits
- Partnership supports global nutraceutical and pharma supply chains

Strategic outlook and innovation roadmap

The collaboration marks a significant step in Novelix’s strategy to expand its nutraceutical portfolio and enter high-growth global markets. The company plans to scale production rapidly and explore downstream applications in cosmetics, functional foods, and clinical nutrition.

Industry experts view the partnership as a model for Indo-German biotech cooperation, combining research excellence with scalable manufacturing.

Sources: ScanX News Novelix Pharmaceuticals Annual Report Economic Times